Patients with GOF mutations in PLCG2 develop autoinflammation and PLCγ2‐associated antibody deficiency and immune dysregulation (APLAID). This evidence concerns the gene PLCG2 and autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation.